Acomplia
Acomplia & Smoking Cessation
About Acomplia
Acomplia Clinical Study
Acomplia Pharmacy Information
Rimonabant and ObesityAcomplia and TobaccoCannabinoid ReceptorsAcomplia Side EffectsSanofi Aventis
Rimonabant: Diet Pill Extraordinaire : Acomplia

Tipped as a future multibillion-dollar-a-year seller, Acomplia is all set to surprise the weight loss drug market. Acomplia has dual advantage attached to it property since it can help people both lose weight and quit smoking. That is really lot more than you can ever expect from even a miracle pill.

Acomplia pills are the newest entrant in the UK pharmaceutical market making waves for its dual nature of weight loss and smoking cessation property. As the wonder drug Accomplia is finally approved for sale through prescription, we have got numerous queries on the online buying options related to this drug.

Rimonabant (acomplia) works by blocking the CB-1 receptors that governs food intake and tobacco dependency. The receptors are in the brain, but also throughout the body, notably in fat cells. Among other things, they account for the sudden surge of appetite felt by people who smoke marijuana.

Doctors say that this system of receptors is disrupted by tobacco and by chronic overeating. The drug restores the balance in the system, reducing dependence on tobacco and suppressing appetite. Since many smokers are also overweight, Acomplia could end up doing double duty.

How it works:
Rimonabant Acomplia's novel mode of action targets the same biological "switch" in the brain that makes people hungry when they smoke cannabis. The drug binds to and blocks a so-called cannabinoid receptor protein found on the surface of brain cells.

Obese patients treated for one year on the highest dose of 20 mg per day shed an average of 19 pounds and lost 3.5 inches of waistline, researchers showed, while 39 percent lost more than one-10th of their body weight.

The drug also boosted levels of "good" HDL cholesterol in the blood by 27 percent.

SlimAlert News
SlimAlert Newsletter

Sanofi still hopeful of making way
Sanofi-Aventis still anticipates that its diet drug acomplia will exceed the FDA's approval process to be marketed in the United States..... 31 July 2007

Sign up for free Newsletter for Special Offers & News for Acomplia